Key clinical point: Patients with intermediate left main disease (LMD) are at higher risk of cardiovascular events.
Major finding: The primary outcome rate was significantly higher in those with intermediate LMD, in contrast to those without intermediate LMD (adjusted hazard ratio, 1.31; P = .0123).
Study details: A substudy of 3,699 patients from the ISCHEMIA trial.
Disclosures: ISCHEMIA was supported by grants from the National Heart, Lung, and Blood Institute. Dr. Bangalore is a member of the advisory board and/or a board member for Meril, SMT, Pfizer, Amgen, Biotronik, and Abbott. He also is a consultant for Reata Pharmaceuticals
Bangalore S et al. SCAI 2020, Abstract 11656.